Biosimilars Month in Review: July 2023

The biosimilar month in review highlights the July 1 launch of 7 adalimumab (Humira) biosimilars in the US and the cost-saving potential of increased biosimilar availability.

Related Keywords

United States ,Poland ,Polish ,Stephen Pagnotta ,Juliana Reed ,Adalimumab Biosimilars ,Samsung Bioepis ,Drug Administration ,Boehringer Ingelheim ,Biosimilars Forum ,Saving Potential ,